Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease.
作者信息
Satoh Hiroaki, Hattori Sou
机构信息
Mito Medical Centre, University of Tsukuba, Japan.
出版信息
Contemp Oncol (Pozn). 2022;26(2):155-156. doi: 10.5114/wo.2022.118004. Epub 2022 Jun 30.
Abstract
摘要
相似文献
1
Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease.
Contemp Oncol (Pozn). 2022;26(2):155-156. doi: 10.5114/wo.2022.118004. Epub 2022 Jun 30.
2
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.
3
Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
JAMA Netw Open. 2021 May 3;4(5):e218787. doi: 10.1001/jamanetworkopen.2021.8787.
4
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
5
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001282.
6
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
J Comp Eff Res. 2019 Jul;8(10):733-751. doi: 10.2217/cer-2018-0130. Epub 2019 Jun 25.
7
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19.
8
Nivolumab plus ipilimumab in non-small-cell lung cancer.
Future Oncol. 2019 Jul;15(19):2287-2302. doi: 10.2217/fon-2019-0031. Epub 2019 May 8.
9
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.
Immunotherapy. 2022 Apr;14(5):295-307. doi: 10.2217/imt-2021-0273. Epub 2022 Jan 25.
10
Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.
Front Pharmacol. 2021 Jul 5;12:573852. doi: 10.3389/fphar.2021.573852. eCollection 2021.
本文引用的文献
1
Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients.
Cancer Diagn Progn. 2021 Nov 3;1(5):485-490. doi: 10.21873/cdp.10065. eCollection 2021 Nov-Dec.
2
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
BioDrugs. 2022 Mar;36(2):137-151. doi: 10.1007/s40259-022-00515-z. Epub 2022 Feb 11.
3
Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.
Kidney Int. 2021 Sep;100(3):516-526. doi: 10.1016/j.kint.2021.06.028. Epub 2021 Jul 9.
4
Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Pol Arch Intern Med. 2021 Feb 26;131(2):152-160. doi: 10.20452/pamw.15776. Epub 2021 Jan 25.
5
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Cancer Treat Rev. 2021 Jan;92:102134. doi: 10.1016/j.ctrv.2020.102134. Epub 2020 Dec 3.
6
Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor.
CEN Case Rep. 2020 May;9(2):114-121. doi: 10.1007/s13730-019-00437-w. Epub 2019 Dec 13.
7
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Oncologist. 2019 Jun;24(6):735-742. doi: 10.1634/theoncologist.2018-0764. Epub 2019 Mar 22.
8
Renal effects of immune checkpoint inhibitors.
Nephrol Dial Transplant. 2017 Jun 1;32(6):936-942. doi: 10.1093/ndt/gfw382.
9
The complexity of aging: cancer risk among elderly people and infectious risk among those with cancer.
Anticancer Agents Med Chem. 2013 Nov;13(9):1444-8. doi: 10.2174/18715206113136660346.
10
Carboplatin-related hematuria and acute renal failure.
Am J Kidney Dis. 1998 Nov;32(5):E5. doi: 10.1016/s0272-6386(98)70152-0.
Zotero 插件